Fig. 3From: Radiopharmacokinetic modelling and radiation dose assessment of 223Ra used for treatment of metastatic castration-resistant prostate cancerCumulative urinary and faecal excretion of 223Ra after intravenous injection as modelled for the present work. Data of patients from three clinical trials [8, 10, 11] are shown with mean values or mean ± SD, or ranges (in parentheses)Back to article page